Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer

Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer

Despite the advances in targeted therapies and immunotherapy for non-small cell lung cancer (NSCLC) patients, the intravenous administration of carboplatin (CARB) and paclitaxel (PTX) in well-spaced cycles is widely indicated for the treatment of NSCLC from stage II to stage IV. Our strategy was to...

Full description

Bibliographic Details
Main Authors: S. Chraibi, R. Rosière, E. De Prez, P. Gérard, MH. Antoine, I. Langer, J. Nortier, M. Remmelink, K. Amighi, N. Wauthoz
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Regenerative anaemia
Thrombocytopenia
Acute kidney injury
Cytotoxicity
Therapeutic intensification
Dry powder for inhalation
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221004984

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221004984

Similar Items